FDA Finalizes Guidance for Prescription-Drug Companion Apps

The U.S. Food and Drug Administration (FDA) has finalized guidance addressing prescription-drug companion apps and related software. The recommendations clarify how companies should distinguish promotional app content from information that constitutes FDA-required labeling, when an app should be referenced in prescribing information, and what information manufacturers should submit to the agency. The guidance is relevant to drug manufacturers and software developers building or maintaining digital tools connected to prescription medicines.

The guidance provides a regulatory reference point for products operating at the intersection of pharmaceuticals and information technology. Drug manufacturers and their technology partners should review app design, the evidence supporting claimed clinical benefits, labeling practices, and FDA submission procedures against the recommendations. The distinction between promotional material and required labeling is particularly consequential: companies need to assess how users encounter app content and how that content relates to approved drug information, rather than treating an app as separate from the medicine’s overall communications and compliance context.

For government contractors and acquisition teams, the announcement is a product-evaluation and vendor-engagement signal, not a procurement opportunity. Agencies or government buyers considering products that include prescription-drug companion apps can incorporate the guidance into technical discussions, product assessments, and questions about labeling and submission practices. It may help buyers understand a vendor’s approach to regulatory alignment, but the source does not establish a new government requirement, create a solicitation, or identify funding for app development or acquisition.

FDA Deputy Commissioner for Technology Jared Seehafer, M.S., described the purpose of finalizing the guidance: “Finalizing this guidance gives drug companies and their technology partners a stable foundation to build on as these technologies advance and helps ensure patients and providers can trust the information they receive.” For GovCon stakeholders, that statement underscores the value of a clearer planning baseline for industry participants. Contractors supporting healthcare technology should monitor how manufacturers apply the recommendations and be prepared to discuss the handling of app content, supporting evidence, prescribing-information references, and agency submissions when relevant to a product review or customer conversation.

• The FDA finalized guidance for prescription-drug companion apps and related software; the signal does not describe a contract award or solicitation.
• The recommendations cover distinguishing promotional app content from FDA-required labeling.
• Manufacturers should assess when a companion app should be referenced in prescribing information.
• The guidance addresses what information companies should submit to the FDA.
• Drug manufacturers and software developers should review app design, clinical-benefit evidence, labeling, and submission practices against the recommendations.
• Government buyers evaluating related products can use the guidance to inform technical discussions and product assessments.
• The source identifies no contract value, procurement funding, solicitation, or funding opportunity.
• Jared Seehafer, M.S., FDA Deputy Commissioner for Technology, said the final guidance provides a “stable foundation” and supports trust in information received by patients and providers.
• Contractors can treat the guidance as a regulatory and product-review consideration, not as a new mandatory procurement requirement.